Similar studies have been done in the past, A 2022 retrospective cohort study reported longer use and higher dose of GLP-1 RAs were associated with a decreased risk of hospitalization for ischemic stroke among Asian patients with T2DM who did not have established atherosclerotic cardiovascular diseases, but who did have dyslipidemia or hypertension (20). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.